Severe leucopenia associated with Sitagliptin use.
Pitocco
Dario
D
Department of Internal Medicine, Diabetes Care Unit, Catholic University School of Medicine, Rome, Italy. dario.pitocco@rm.unicatt.it
Zaccardi
Francesco
F
Martini
Francesca
F
Scavone
Giuseppe
G
Musella
Tittania
T
Caputo
Salvatore
S
Ghirlanda
Giovanni
G
D000368:Aged; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D007970:Leukopenia / Q000139:chemically induced* / Q000175:diagnosis*; D008297:Male; D011719:Pyrazines / Q000009:adverse effects* / Q000627:therapeutic use*; D000068900:Sitagliptin Phosphate; D014230:Triazoles / Q000009:adverse effects* / Q000627:therapeutic use*
D007004:Hypoglycemic Agents; D011719:Pyrazines; D014230:Triazoles; D000068900:Sitagliptin Phosphate